QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbols(s) |
Name of each exchange on which registered | ||
☒ | Accelerated filer | ☐ | ||||
Non-accelerated filer | ☐ | Smaller reporting company | ||||
Emerging growth company |
Class |
Outstanding at November 2 , 2021 | |
Common Stock, $0.01 par value per share |
ITEM 1. |
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS |
September 30, 2021 |
December 31, 2020 |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Short-term investments |
||||||||
Accounts receivable, net |
||||||||
Inventories |
||||||||
Assets held for sale |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
Property, plant and equipment, net |
||||||||
Goodwill |
||||||||
Intangible assets, net |
||||||||
Assets held for sale |
|
|
|
|
|
|
|
|
Other long-term assets |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Current portion of long-term debt |
$ | $ | ||||||
Accounts payable |
||||||||
Customer advances |
||||||||
Other current liabilities |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Long-term debt |
||||||||
Other long-term liabilities |
||||||||
Commitments and contingencies (Note 14) |
||||||||
Redeemable noncontrolling interest |
||||||||
Shareholders’ equity: |
||||||||
Preferred stock, $ |
||||||||
Common stock, $ |
||||||||
Treasury stock, at cost, |
( |
) | ( |
) | ||||
Accumulated other comprehensive income (loss) |
( |
) |
||||||
Other shareholders’ equity |
||||||||
|
|
|
|
|||||
Total shareholders’ equity attributable to Bruker Corporation |
||||||||
Noncontrolling interest in consolidated subsidiaries |
||||||||
|
|
|
|
|||||
Total shareholders’ equity |
||||||||
|
|
|
|
|||||
Total liabilities, redeemable noncontrolling interest and shareholders’ equity |
$ | $ | ||||||
|
|
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Product revenue |
$ | $ | $ | $ | ||||||||||||
Service revenue |
||||||||||||||||
Other revenue |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total revenue |
||||||||||||||||
Cost of product revenue |
||||||||||||||||
Cost of service revenue |
||||||||||||||||
Cost of other revenue |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total cost of revenue |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
||||||||||||||||
Operating expenses: |
||||||||||||||||
Selling, general and administrative |
||||||||||||||||
Research and development |
||||||||||||||||
Other charges, net |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating income |
||||||||||||||||
Interest and other income (expense), net |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries |
||||||||||||||||
Income tax provision |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Consolidated net income |
||||||||||||||||
Net income attributable to noncontrolling interests in consolidated subsidiaries |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income attributable to Bruker Corporation |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income per common share attributable to Bruker Corporation shareholders: |
||||||||||||||||
Basic |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Diluted |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average common shares outstanding: |
||||||||||||||||
Basic |
||||||||||||||||
Diluted |
||||||||||||||||
Comprehensive income |
$ | $ | $ | $ | ||||||||||||
Less: Comprehensive income attributable to noncontrolling interests |
||||||||||||||||
Less: Comprehensive loss attributable to redeemable noncontrolling interest |
( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Comprehensive income attributable to Bruker Corporation |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Redeemable Noncontrolling Interest |
Common Shares |
Common Stock Amount |
Treasury Shares |
Treasury Stock Amount |
Additional Paid-In Capital |
Retained Earnings |
Accumulated Other Comprehensive Income (Loss) |
Total Shareholders’ Equity Attributable to Bruker Corporation |
Noncontrolling Interests in Consolidated Subsidiaries |
Total Shareholders’ Equity |
||||||||||||||||||||||||||||||||||
Balance at December 31, 2020 |
$ | $ | $ | ( |
) | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Shares purchased |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($ |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income |
||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at March 31, 2021 |
$ | — | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | |||||||||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Shares purchased |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($ |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Formation of Acuity Spatial Genomics Inc. |
— | — | ||||||||||||||||||||||||||||||||||||||||||
Consolidated net income |
— | |||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at June 30, 2021 |
$ | $ | $ | ( |
) | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($ |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income |
— | |||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at September 30, 2021 |
$ | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | |||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable Noncontrolling Interest |
Common Shares |
Common Stock Amount |
Treasury Shares |
Treasury Stock Amount |
Additional Paid-In Capital |
Retained Earnings |
Accumulated Other Comprehensive Income (Loss) |
Total Shareholders’ Equity Attributable to Bruker Corporation |
Noncontrolling Interests in Consolidated Subsidiaries |
Total Shareholders’ Equity |
||||||||||||||||||||||||||||||||||
Balance at December 31, 2019 |
$ | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | |||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($ |
— | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||
Acquired remaining |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Consolidated net income |
— | |||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at March 31, 2020 |
$ | — | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Shares Repurchased |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($ |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income |
||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income |
||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at June 30, 2020 |
$ | — | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||||
Stock options exercised |
— | |||||||||||||||||||||||||||||||||||||||||||
Restricted stock units vested |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Stock based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Shares Repurchased |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($ |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income |
||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income |
||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at September 30, 2020 |
$ | — | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities: |
||||||||
Consolidated net income |
$ | $ | ||||||
Adjustments to reconcile consolidated net income to cash flows from operating activities: |
||||||||
Depreciation and amortization |
||||||||
Stock-based compensation expense |
||||||||
Deferred income taxes |
( |
) | ||||||
Other non-cash expenses, net |
||||||||
Changes in operating assets and liabilities, net of acquisitions and divestitures: |
||||||||
Accounts receivable |
( |
) | ||||||
Inventories |
( |
) | ( |
) | ||||
Accounts payable and accrued expenses |
( |
) | ||||||
Income taxes payable, net |
( |
) | ( |
) | ||||
Deferred revenue |
||||||||
Customer advances |
( |
) | ||||||
Other changes in operating assets and liabilities, net |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net cash provided by operating activities |
||||||||
|
|
|
|
|||||
Cash flows from investing activities: |
||||||||
Purchases of short-term investments |
( |
) | ( |
) | ||||
Maturity of short-term investments |
||||||||
Purchases of investments held to maturity |
( |
) | ||||||
Cash paid for acquisitions, net of cash acquired |
( |
) | ( |
) | ||||
Purchases of property, plant and equipment |
( |
) | ( |
) | ||||
Proceeds from sales of property, plant and equipment |
||||||||
Net proceeds from cross currency swap agreements |
||||||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash flows from financing activities: |
||||||||
Repayments of revolving lines of credit |
( |
) | ||||||
Proceeds from revolving lines of credit |
— | |||||||
Repayment of other debt |
( |
) | ( |
) | ||||
Proceeds from other debt |
||||||||
Payment of deferred financing costs |
— | ( |
) | |||||
Proceeds from issuance of common stock, net |
||||||||
Payment of contingent consideration |
( |
) | ( |
) | ||||
Payment of dividends to common stockholders |
( |
) | ( |
) | ||||
Purchases of common stock |
( |
) | ( |
) | ||||
Cash payments to noncontrolling interest |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in financing activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
( |
) | ||||||
|
|
|
|
|||||
Net change in cash, cash equivalents and restricted cash |
( |
) | ( |
) | ||||
Cash, cash equivalents and restricted cash at beginning of period |
||||||||
|
|
|
|
|||||
Cash, cash equivalents and restricted cash at end of period |
$ | $ | ||||||
|
|
|
|
|||||
Supplemental disclosure of cash flow information: |
||||||||
Restricted cash period beginning balance |
$ | $ | ||||||
|
|
|
|
|||||
Restricted cash period ending balance |
$ | $ | ||||||
|
|
|
|
1. |
Description of Business |
2. |
Recent Accounting Pronouncements |
3. |
Revenue |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Revenue by Group: |
||||||||||||||||
Bruker BioSpin |
$ | $ | $ | $ | ||||||||||||
Bruker CALID |
||||||||||||||||
Bruker Nano |
||||||||||||||||
BEST |
||||||||||||||||
Eliminations |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Total revenue |
$ | $ | $ | $ | ||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Revenue by End Customer Geography: |
||||||||||||||||
United States |
$ | $ | $ | $ | ||||||||||||
Germany |
||||||||||||||||
Rest of Europe |
||||||||||||||||
Asia Pacific |
||||||||||||||||
Other |
||||||||||||||||
Total revenue |
$ | $ | $ | $ | ||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Revenue recognized at a point in time |
$ | $ | $ | $ | ||||||||||||
Revenue recognized over time |
||||||||||||||||
Total revenue |
$ | $ | $ | $ | ||||||||||||
4. |
Acquisitions |
Consideration Transferred: |
||||
Cash paid |
$ | |
||
Fair value of contingent consideration |
||||
Working capital adjustment |
( |
) | ||
Total consideration transferred |
$ | |||
Allocation of Consideration Transferred: |
||||
Inventories |
$ | |||
Other current and non-current assets |
||||
Intangible assets: |
||||
Technology |
||||
Customer relationships |
||||
Trade name |
||||
Backlog |
||||
Goodwill |
||||
Liabilities assumed |
( |
) | ||
Total consideration allocated |
$ | |||
Name of Acquisition |
Date Acquired |
Segment |
Total Consideration |
Cash Consideration |
||||||||||||
Creative Instruments |
July 1, 2021 |
BSI Life Science |
$ | $ | ||||||||||||
SVXR, Inc. |
September 9, 2021 |
BSI Nano | ||||||||||||||
$ | $ | |||||||||||||||
Name |
Acquisition / Investment |
Date Acquired |
Segment |
Consideration |
Cash Consideration |
|||||||||||||||
Glycopath Inc. |
Investment | February 18, 2021 | BSI Life Science | $ | $ | |||||||||||||||
IonPath Inc. |
Investment | March 18, 2021 | BSI Life Science | |||||||||||||||||
Olaris, Inc. |
Investment | September 23, 2021 | BSI Life Science | |||||||||||||||||
$ | $ | |||||||||||||||||||
5. |
Inventories |
September 30, 2021 |
December 31, 2020 |
|||||||
Raw materials |
$ | $ | ||||||
Work-in-process |
||||||||
Finished goods |
||||||||
Demonstration units |
||||||||
|
|
|
|
|||||
Inventories |
$ | $ | ||||||
|
|
|
|
6. |
Goodwill and Intangible |
Total |
||||
Balance at December 31, 2020 |
$ | |||
Current period additions/adjustments |
||||
Foreign currency impact |
( |
) | ||
|
|
|||
Balance at September 30, 2021 |
$ | |||
|
|
September 30, 2021 |
December 31, 2020 |
|||||||||||||||||||||||
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
|||||||||||||||||||
Existing technology and related patents |
$ | $ | ( |
) | $ | $ | $ | ( |
) | $ | ||||||||||||||
Customer relationships |
( |
) | ( |
) | ||||||||||||||||||||
Trade names |
( |
) | ( |
) | ||||||||||||||||||||
Other |
( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Intangible assets |
$ | $ | ( |
) | $ | $ | $ | ( |
) | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
7. |
Debt |
September 30, 2021 |
December 31, 2020 |
|||||||
US Dollar notes under the 2012 Note Purchase Agreement |
$ | $ |
||||||
CHF notes (in dollars) under the 2019 Note Purchase Agreement |
||||||||
US Dollar notes under the 2019 Term Loan |
||||||||
Unamortized debt issuance costs |
( |
) | ( |
) | ||||
Finance lease obligations and other loans |
||||||||
|
|
|
|
|||||
Total debt |
||||||||
Current portion of long-term debt |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total long-term debt, less current portion |
$ | $ | ||||||
|
|
|
|
Weighted Average Interest Rate |
Total Amount Committed by Lenders |
Outstanding Borrowings |
Outstanding Letters of Credit |
Total Amount Available |
||||||||||||||||
2019 Credit Agreement |
% | $ | $ | — | $ | $ | ||||||||||||||
Bank guarantees and working capital line |
varies | — | — | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total revolving lines of credit |
$ | $ | — | $ | $ | |||||||||||||||
|
|
|
|
|
|
|
|
8. |
Fair Value of Financial |
September 30, 2021 |
Total |
Quoted Prices in Active Markets Available (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Unobservable Inputs (Level 3) |
||||||||||||
Assets: |
||||||||||||||||
Time deposits and money market funds |
$ | $ | — | $ | $ | — | ||||||||||
Short-term investments |
— | — | ||||||||||||||
Interest rate and cross currency swap agreements |
— | — | ||||||||||||||
Fixed price commodity contracts |
— | — | ||||||||||||||
Debt securities available for sale |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets recorded at fair value |
$ | $ | — | $ | $ | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Liabilities: |
||||||||||||||||
Contingent consideration |
$ | $ | — | $ | — | $ | ||||||||||
Hybrid instrument liability |
— | — | ||||||||||||||
Interest rate and cross currency swap agreements |
— | — | ||||||||||||||
Embedded derivatives in purchase and delivery contracts |
— | — | ||||||||||||||
Forward currency contracts |
— | — | ||||||||||||||
Long-term fixed interest rate debt |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities recorded at fair value |
$ | $ | — | $ | $ | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
December 31, 2020 |
Total |
Quoted Prices in Active Markets Available (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Unobservable Inputs (Level 3) |
||||||||||||
Assets: |
||||||||||||||||
Time deposits and money market funds |
$ | $ | — | $ | $ | — | ||||||||||
Short-term investments |
— | — | ||||||||||||||
Interest rate and cross currency swap agreements |
— | — | ||||||||||||||
Forward currency contracts |
— | — | ||||||||||||||
Embedded derivatives in purchase and delivery contracts |
— | — | ||||||||||||||
Fixed price commodity contracts |
— | — | ||||||||||||||
Debt securities available for sale |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets recorded at fair value |
$ | $ | — | $ | $ | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Liabilities: |
||||||||||||||||
Contingent consideration |
$ | $ | — | $ | — | $ | ||||||||||
Hybrid instrument liability |
— | — | ||||||||||||||
Interest rate and cross currency swap agreements |
— | — | ||||||||||||||
Forward currency contracts |
— | — | ||||||||||||||
Long-term fixed interest rate debt |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities recorded at fair value |
$ | $ | — | $ | $ | |||||||||||
|
|
|
|
|
|
|
|
Balance at December 31, 2020 |
$ | |||
Current period additions |
||||
Current period adjustments |
( |
) | ||
Current period settlements |
( |
) | ||
Foreign currency effect |
( |
) | ||
|
|
|||
Balance at September 30, 2021 |
$ | |||
|
|
Balance at December 31, 2020 |
$ | |||
Current period adjustments |
||||
Foreign currency effect |
( |
) | ||
|
|
|||
Balance at September 30, 2021 |
$ | |||
|
|
9. |
Derivative Instruments and Hedging Activities |
September 30, 2021 |
December 31, 2020 |
|||||||||||||||
Notional Amount in U.S. Dollars |
Fair Value |
Notional Amount in U.S. Dollars |
Fair Value |
|||||||||||||
Forward currency contracts (1): |
||||||||||||||||
Assets |
$ | $ | — | $ | $ | |||||||||||
Liabilities |
( |
) | ( |
) | ||||||||||||
Cross-currency and interest rate swap agreements (2): |
||||||||||||||||
Liabilities |
( |
) | ( |
) | ||||||||||||
Long-term debt |
||||||||||||||||
Liabilities |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
|
|
|
|
|
|
|
|
(1) | Derivatives not designated as accounting hedges. |
(2) | Derivatives designated as accounting hedges. |
September 30, 2021 |
December 31, 2020 |
|||||||
Derivatives designated as hedging instruments |
||||||||
Interest rate cross-currency swap agreements |
||||||||
Other current assets |
$ | $ | ||||||
Other current liabilities |
( |
) | ( |
) | ||||
Other long-term liabilities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
( |
) | ( |
) | |||||
Long-term debt |
||||||||
Long-term debt |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total derivatives designated as hedging instruments |
$ |
( |
) | $ |
( |
) | ||
|
|
|
|
|||||
Derivatives not designated as hedging instruments |
||||||||
Forward currency contracts |
||||||||
Other current assets |
$ | — | $ | |||||
Other current liabilities |
( |
) | ( |
) | ||||
Embedded derivatives in purchase and delivery contracts |
||||||||
Other current assets |
— | |||||||
Other current liabilities |
( |
) | — | |||||
Fixed price commodity contracts |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total derivatives not designated as hedging instruments |
||||||||
|
|
|
|
|||||
Total derivatives |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
Location of gain (loss) recognized in income on derivative |
||||||||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||||
|
2021 |
2020 |
2021 |
2020 |
||||||||||||||
Derivatives not designated as hedging instruments |
||||||||||||||||||
Forward currency contracts |
Interest and other income (expense), net | $ |
( |
) | $ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||||
Embedded and delivery contracts |
Interest and other income (expense), net | ( |
) |
( |
) |
|||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
( |
) | ( |
) |
( |
) |
|||||||||||||
Derivatives designated as cash flow hedging instruments |
||||||||||||||||||
Interest rate cross-currency swap agreements |
Interest and other income (expense), net | $ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||||
Derivatives designated as net investment hedging instruments |
||||||||||||||||||
Interest rate cross-currency swap agreements |
Interest and other income (expense), net | |||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||
|
|
|
|
|
|
|
|
Amount of unrealized gain (loss) on contracts recognized in other comprehensive income (loss) |
||||||||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||||
Financial Statement Classification |
2021 |
2020 |
2021 |
2020 |
||||||||||||||
Derivatives designated as cash flow hedging instruments |
||||||||||||||||||
Interest rate cross-currency swap agreements |
|
Accumulated other comprehensive income, net of tax | $ |
$ |
( |
) |
$ |
$ |
( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||||
$ |
$ |
( |
) |
$ |
$ |
( |
) | |||||||||||
Derivatives designated as net investment hedging instruments |
||||||||||||||||||
Interest rate cross-currency swap agreements |
Accumulated other comprehensive income, net of tax | $ |
$ |
( |
) |
$ |
$ |
( |
) | |||||||||
Long-term debt |
Accumulated other comprehensive income, net of tax | ( |
) |
( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
$ |
$ |
( |
) |
$ |
$ |
( |
) | |||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total |
$ |
$ |
( |
) |
$ |
$ |
( |
) | ||||||||||
|
|
|
|
|
|
|
|
10. |
Provision for Income Taxes |
11. |
Earnings Per Share |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Net income attributable to Bruker Corporation, as reported |
$ | $ | $ | $ | ||||||||||||
Weighted average shares outstanding: |
||||||||||||||||
Weighted average shares outstanding-basic |
||||||||||||||||
Effect of dilutive securities: |
||||||||||||||||
Stock options and restricted stock awards and units |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income per common share attributable to Bruker Corporation shareholders: Basic |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Diluted |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Stock options |
||||||||||||||||
Unvested restricted stock units |
12. |
Shareholders’ Equity |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Consolidated net income |
$ | $ | $ | $ | ||||||||||||
Foreign currency translation adjustments |
( |
) | ( |
) | ||||||||||||
Derivatives designated as hedging instruments, net of tax |
( |
) | ( |
) | ||||||||||||
Pension liability adjustments, net of tax |
||||||||||||||||
Net comprehensive income |
||||||||||||||||
Less: Comprehensive income attributable to noncontrolling interests |
||||||||||||||||
Less: Comprehensive loss attributable to redeemable noncontrolling interest |
— | — | — | ( |
) | |||||||||||
Comprehensive income attributable to Bruker Corporation |
$ | $ | $ | $ | ||||||||||||
Foreign Currency Translation |
Derivatives Designated as Hedging Instruments |
Pension Liability Adjustment |
Accumulated Other Comprehensive Income (Loss) |
|||||||||||||
Balance at December 31, 2020 |
$ | $ | ( |
) | $ | ( |
) | $ | ||||||||
Other comprehensive (loss) income before reclassifications, net of tax |
( |
) | ( |
) | ||||||||||||
Realized loss on amounts reclassified from other comprehensive income, net of tax |
— | — | ||||||||||||||
Net current period other comprehensive (loss) income |
( |
) | ( |
) | ||||||||||||
Balance at September 30, 2021 |
$ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Costs of product revenue |
$ | $ | $ | $ | ||||||||||||
Selling, general and administrative |
||||||||||||||||
Research and development |
||||||||||||||||
Total stock-based compensation |
$ | $ | $ | $ | ||||||||||||
Nine months ended | ||||||||
September 30, | ||||||||
2021 | 2020 | |||||||
Risk-free interest rates |
% | % | ||||||
Expected life |
||||||||
Volatility |
% | % | ||||||
Expected dividend yield |
% | % |
Shares Subject to Options |
Weighted Average Option Price |
Weighted Average Remaining Contractual Term (Yrs) |
Aggregate Intrinsic Value (in millions) (b) |
|||||||||||||
Outstanding at December 31, 2020 |
$ | |||||||||||||||
Granted |
$ | |||||||||||||||
Exercised |
( |
) | $ | |||||||||||||
Forfeited/Expired |
— | $ | — | |||||||||||||
Outstanding at September 30, 2021 |
$ | $ | ||||||||||||||
Exercisable at September 30, 2021 |
$ | $ | ||||||||||||||
Exercisable and expected to vest at September 30, 2021 (a) |
$ | $ | ||||||||||||||
(a) |
Represents the number of vested options at September 30, 2021, plus the number of unvested options at September 30, 2021 that are ultimately expected to vest based on our estimated forfeiture rate. |
(b) | The aggregate intrinsic value is based on the positive difference between the exercise price of the underlying options and the quoted price of our common stock on September 30, 2021. |
Shares Subject to Restriction |
Weighted Average Grant Date Value |
|||||||
Outstanding at December 31, 2020 |
$ | |||||||
Granted |
$ | |||||||
Vested |
( |
) | $ | |||||
Forfeited |
( |
) | $ | |||||
Outstanding at September 30, 2021 |
$ | |||||||
13. |
Other Charges, Net |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Information technology transformation costs |
$ | $ | $ | $ | ||||||||||||
Professional fees incurred in connection with investigation matters |
||||||||||||||||
Restructuring charges |
||||||||||||||||
Acquisition-related charges |
( |
) | ||||||||||||||
Long-lived asset impairments |
( |
) |
( |
) |
||||||||||||
Other |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Other charges, net |
$ | $ | $ | |
$ | |||||||||||
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Cost of revenues |
$ | $ | $ | $ | ||||||||||||
Other charges, net |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
$ | $ | $ | $ | |||||||||||||
|
|
|
|
|
|
|
|
Total |
Severance |
Exit Costs |
Provisions for Excess Inventory |
|||||||||||||
Balance at December 31, 2020 |
$ | $ | $ | $ | ||||||||||||
Restructuring charges |
— | |||||||||||||||
Cash payments |
( |
) | ( |
) | ( |
) | — | |||||||||
Other, non-cash adjustments and foreign currency effect |
( |
) | — | ( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance at September 30, 2021 |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
14. |
Commitments and Contingencies |
15. |
Business Segment Information |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Revenue: |
||||||||||||||||
BSI Life Science |
$ | $ | $ | $ | ||||||||||||
BSI NANO |
||||||||||||||||
BEST |
||||||||||||||||
Eliminations (a) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Total revenue |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating Income (loss) |
||||||||||||||||
BSI Life Science |
$ | $ | $ | $ | ||||||||||||
BSI NANO |
||||||||||||||||
BEST |
||||||||||||||||
Corporate, eliminations and other (b) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating income |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
(a) | Represents product and service revenue between reportable segments. |
(b) | Represents corporate costs and eliminations not allocated to the reportable segments. |
September 30, 2021 |
December 31, 2020 |
|||||||
Assets: |
||||||||
BSI Life Science, BSI NANO & Corporate |
$ | $ | ||||||
BEST |
||||||||
Eliminations and other (a) |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
(a) | Assets not allocated to the reportable segments and eliminations of intercompany transactions. |
ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Nine Months Ended September 30, |
||||||||
2021 |
2020 |
|||||||
Net cash provided by operating activities |
$ | 143.8 | $ | 129.2 | ||||
Less: purchases of property, plant and equipment |
(63.6 | ) | (68.4 | ) | ||||
|
|
|
|
|||||
Free cash flow |
$ | 80.2 | $ | 60.8 | ||||
|
|
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||||||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||||||||||||||||||
Gross profit |
$ | 308.7 | 50.7 | % | $ | 248.3 | 48.6 | % | $ | 868.0 | 50.0 | % | $ | 626.8 | 46.1 | % | ||||||||||||||||
Non-GAAP adjustments: |
||||||||||||||||||||||||||||||||
Restructuring costs |
0.2 | — | 0.3 | — | 1.6 | 0.1 | % | 1.3 | 0.1 | % | ||||||||||||||||||||||
Acquisition-related costs |
0.1 | — | 0.5 | 0.1 | % | 0.1 | — | 0.5 | — | |||||||||||||||||||||||
Purchased intangible amortization |
5.3 | 0.9 | % | 5.0 | 1.0 | % | 15.0 | 0.9 | % | 15.1 | 1.1 | % | ||||||||||||||||||||
Other costs |
0.6 | 0.1 | % | (0.3 | ) | (0.1 | %) | 0.1 | — | (0.1 | ) | — | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Non-GAAP gross profit |
$ | 314.9 | 51.7 | % | $ | 253.8 | 49.6 | % | $ | 884.8 | 51.0 | % | $ | 643.6 | 47.3 | % | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||||||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||||||||||||||||||
Operating income |
$ | 113.2 | 18.6 | % | $ | 81.2 | 15.9 | % | $ | 287.9 | 16.6 | % | $ | 135.5 | 9.9 | % | ||||||||||||||||
Non-GAAP adjustments: |
||||||||||||||||||||||||||||||||
Restructuring costs |
1.1 | 0.2 | % | 1.9 | 0.4 | % | 5.2 | 0.3 | % | 5.7 | 0.4 | % | ||||||||||||||||||||
Acquisition-related costs |
0.7 | 0.1 | % | 1.4 | 0.3 | % | 3.9 | 0.2 | % | (0.5 | ) | — | ||||||||||||||||||||
Purchased intangible amortization |
9.2 | 1.5 | % | 9.1 | 1.8 | % | 27.2 | 1.6 | % | 26.8 | 2.0 | % | ||||||||||||||||||||
Other costs |
1.2 | 0.2 | % | 1.3 | 0.2 | % | 2.2 | 0.1 | % | 8.6 | 0.6 | % | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Non-GAAP operating income |
$ | 125.4 | 20.6 | % | $ | 94.9 | 18.6 | % | $ | 326.4 | 18.8 | % | $ | 176.1 | 12.9 | % | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
• | the impact of the COVID-19 global pandemic on our customers, supply chain or manufacturing capabilities; |
• | the impact of certain weather-related disruptions, such as the recent flooding in Germany and other parts of Europe; |
• | the timing of governmental stimulus programs and academic research budgets; |
• | the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received; |
• | foreign currency exchange rates; |
• | the time it takes for us to receive critical materials to manufacture our products; |
• | general economic conditions, including the impact of COVID-19 or other factors on the global economy; |
• | the time it takes to satisfy local customs requirements and other export/import requirements; |
• | the time it takes for customers to construct or prepare their facilities for our products; and |
• | the time required to obtain governmental licenses. |
• | Revenue recognition; |
• | Income taxes; |
• | Inventories; |
• | Goodwill, other intangible assets and other long-lived assets; and |
• | Business combinations. |
Three Months Ended September 30, |
||||||||||||||||
2021 |
2020 |
Dollar Change |
Percentage Change |
|||||||||||||
Product revenue |
$ | 508.3 | $ | 419.6 | $ | 88.7 | 21.1 | % | ||||||||
Service revenue |
99.0 | 90.0 | 9.0 | 10.0 | % | |||||||||||
Other revenue |
1.6 | 1.8 | (0.2 | ) | (11.1 | )% | ||||||||||
|
|
|
|
|
|
|||||||||||
Total revenue |
608.9 | 511.4 | 97.5 | 19.1 | % | |||||||||||
Cost of product revenue |
243.5 | 210.3 | 33.2 | 15.8 | % | |||||||||||
Cost of service revenue |
56.5 | 52.6 | 3.9 | 7.4 | % | |||||||||||
Cost of other revenue |
0.2 | 0.2 | — | — | ||||||||||||
|
|
|
|
|
|
|||||||||||
Total cost of revenue |
300.2 | 263.1 | 37.1 | 14.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
308.7 | 248.3 | 60.4 | 24.3 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Selling, general and administrative |
141.3 | 114.6 | 26.7 | 23.3 | % | |||||||||||
Research and development |
52.1 | 48.3 | 3.8 | 7.9 | % | |||||||||||
Other charges, net |
2.1 | 4.2 | (2.1 | ) | (50.0 | )% | ||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
195.5 | 167.1 | 28.4 | 17.0 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating income |
113.2 | 81.2 | 32.0 | 39.4 | % | |||||||||||
Interest and other income (expense), net |
(4.4 | ) | (5.9 | ) | 1.5 | (25.4 | )% | |||||||||
|
|
|
|
|
|
|||||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries |
108.8 | 75.3 | 33.5 | 44.5 | % | |||||||||||
Income tax provision |
20.7 | 20.0 | 0.7 | 3.5 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Consolidated net income |
88.1 | 55.3 | 32.8 | 59.3 | % | |||||||||||
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries |
1.0 | 1.0 | — | — | ||||||||||||
|
|
|
|
|
|
|||||||||||
Net income attributable to Bruker Corporation |
$ | 87.1 | $ | 54.3 | $ | 32.8 | 60.4 | % | ||||||||
|
|
|
|
|
|
Three Months Ended September 30, |
Percentage |
|||||||||||||||
2021 |
2020 |
Dollar Change |
Change |
|||||||||||||
BSI Life Science |
$ | 380.7 | $ | 323.4 | $ | 57.3 | 17.7 | % | ||||||||
BSI NANO |
174.9 | 147.1 | 27.8 | 18.9 | % | |||||||||||
BEST |
57.0 | 43.8 | 13.2 | 30.1 | % | |||||||||||
Eliminations (a) |
(3.7 | ) | (2.9 | ) | (0.8 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
$ | 608.9 | $ | 511.4 | $ | 97.5 | 19.1 | % | |||||||||
|
|
|
|
|
|
(a) | Represents product and service revenue between reportable segments. |
Three Months Ended September 30, |
||||||||||||||||
2021 |
2020 |
|||||||||||||||
Operating Income (Loss) |
Percentage of Segment Revenue |
Operating Income (Loss) |
Percentage of Segment Revenue |
|||||||||||||
BSI Life Science |
$ | 100.9 | 26.5 | % | $ | 80.6 | 24.9 | % | ||||||||
BSI NANO |
21.8 | 12.5 | % | 12.2 | 8.3 | % | ||||||||||
BEST |
7.4 | 13.0 | % | 1.2 | 2.7 | % | ||||||||||
Corporate, eliminations and other (a) |
(16.9 | ) | (12.8 | ) | ||||||||||||
|
|
|
|
|||||||||||||
Total operating income |
$ | 113.2 | 18.6 | % | $ | 81.2 | 15.9 | % | ||||||||
|
|
|
|
(a) | Represents corporate costs and eliminations not allocated to the reportable segments. |
Nine Months Ended September 30, |
||||||||||||||||
2021 |
2020 |
Dollar Change |
Percentage Change |
|||||||||||||
Product revenue |
$ | 1,441.2 | $ | 1,111.6 | $ | 329.6 | 29.7 | % | ||||||||
Service revenue |
287.8 | 244.3 | 43.5 | 17.8 | % | |||||||||||
Other revenue |
5.4 | 4.1 | 1.3 | 31.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total revenue |
1,734.4 | 1,360.0 | 374.4 | 27.5 | % | |||||||||||
Cost of product revenue |
700.4 | 584.1 | 116.3 | 19.9 | % | |||||||||||
Cost of service revenue |
165.3 | 148.4 | 16.9 | 11.4 | % | |||||||||||
Cost of other revenue |
0.7 | 0.7 | — | — | ||||||||||||
|
|
|
|
|
|
|||||||||||
Total cost of revenue |
866.4 | 733.2 | 133.2 | 18.2 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
868.0 | 626.8 | 241.2 | 38.5 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Selling, general and administrative |
407.9 | 338.2 | 69.7 | 20.6 | % | |||||||||||
Research and development |
162.7 | 140.9 | 21.8 | 15.5 | % | |||||||||||
Other charges, net |
9.5 | 12.2 | (2.7 | ) | (22.1 | )% | ||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
580.1 | 491.3 | 88.8 | 18.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating income |
287.9 | 135.5 | 152.4 | 112.5 | % | |||||||||||
Interest and other income (expense), net |
(13.8 | ) | (15.4 | ) | 1.6 | (10.4 | )% | |||||||||
|
|
|
|
|
|
|||||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries |
274.1 | 120.1 | 154.0 | 128.2 | % | |||||||||||
Income tax provision |
69.5 | 30.0 | 39.5 | 131.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Consolidated net income |
204.6 | 90.1 | 114.5 | 127.1 | % | |||||||||||
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries |
3.2 | 1.2 | 2.0 | 166.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Net income attributable to Bruker Corporation |
$ | 201.4 | $ | 88.9 | $ | 112.5 | 126.5 | % | ||||||||
|
|
|
|
|
|
Nine Months Ended September 30, |
Percentage Change |
|||||||||||||||
2021 |
2020 |
Dollar Change |
||||||||||||||
BSI Life Science |
$ | 1,074.3 | $ | 842.6 | $ | 231.7 | 27.5 | % | ||||||||
BSI NANO |
504.6 | 392.7 | 111.9 | 28.5 | % | |||||||||||
BEST |
166.0 | 134.8 | 31.2 | 23.1 | % | |||||||||||
Eliminations (a) |
(10.5 | ) | (10.1 | ) | (0.4 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
$ | 1,734.4 | $ | 1,360.0 | $ | 374.4 | 27.5 | % | |||||||||
|
|
|
|
|
|
(a) | Represents product and service revenue between reportable segments. |
Nine Months Ended September 30, |
||||||||||||||||
2021 |
2020 |
|||||||||||||||
Operating Income (Loss) |
Percentage of Segment Revenue |
Operating Income (Loss) |
Percentage of Segment Revenue |
|||||||||||||
BSI Life Science |
$ | 263.4 | 24.5 | % | $ | 158.7 | 18.8 | % | ||||||||
BSI NANO |
55.1 | 10.9 | % | 9.3 | 2.4 | % | ||||||||||
BEST |
18.3 | 11.0 | % | 5.1 | 3.8 | % | ||||||||||
Corporate, eliminations and other (a) |
(48.9 | ) | (37.6 | ) | ||||||||||||
|
|
|
|
|||||||||||||
Total operating income |
$ | 287.9 | 16.6 | % | $ | 135.5 | 10.0 | % | ||||||||
|
|
|
|
(a) | Represents corporate costs and eliminations not allocated to the reportable segments. |
Nine Months Ended September 30, |
||||||||
2021 |
2020 |
|||||||
Net cash provided by operating activities |
$ | 143.8 | $ | 129.2 | ||||
Net cash used in investing activities |
(143.8 | ) | (163.9 | ) | ||||
Net cash used in financing activities |
(85.6 | ) | (87.3 | ) | ||||
Effect of exchange rates on cash and cash equivalents |
(23.4 | ) | 10.7 | |||||
|
|
|
|
|||||
Total decrease in cash and cash equivalents |
$ | (109.0 | ) | $ | (111.3 | ) | ||
|
|
|
|
September 30, 2021 |
December 31, 2020 |
|||||||
US Dollar notes under the 2012 Note Purchase Agreement |
$ | 205.0 | $ | 205.0 | ||||
CHF notes (in dollars) under the 2019 Note Purchase Agreement |
318.1 | 335.5 | ||||||
US Dollar notes under the 2019 Term Loan |
300.0 | 300.0 | ||||||
Unamortized debt issuance costs |
(2.1 | ) | (2.4 | ) | ||||
Finance lease obligations and other loans |
6.0 | 6.4 | ||||||
|
|
|
|
|||||
Total debt |
827.0 | 844.5 | ||||||
Current portion of long-term debt |
(109.5 | ) | (2.2 | ) | ||||
|
|
|
|
|||||
Total long-term debt, less current portion |
$ | 717.5 | $ | 842.3 | ||||
|
|
|
|
Weighted Average Interest Rate |
Total Amount Committed by Lenders |
Outstanding Borrowings |
Outstanding Letters of Credit |
Total Committed Amounts Available |
||||||||||||||||
2019 Credit Agreement |
1.3 | % | $ | 600.0 | $ | — | $ | 0.1 | $ | 599.9 | ||||||||||
Bank guarantees and working capital line |
varies | 115.2 | — | 115.2 | — | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total revolving lines of credit |
$ | 715.2 | $ | — | $ | 115.3 | $ | 599.9 | ||||||||||||
|
|
|
|
|
|
|
|
ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 4. |
CONTROLS AND PROCEDURES |
ITEM 1. |
LEGAL PROCEEDINGS |
ITEM IA. |
RISK FACTORS |
ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
ITEM 6. |
EXHIBITS |
Exhibit No. |
Description | |
31.1* | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
31.2* | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
32.1* | Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
101.INS* | Inline XBRL Instance Document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 has been formatted in Inline XBRL (included in Exhibit 101) |
* | Filed or furnished herewith. |
Date: November 5, 2021 |
BRUKER CORPORATION | |||||
By: |
/s/ FRANK H. LAUKIEN, PH.D. | |||||
Frank H. Laukien, Ph.D. | ||||||
President, Chief Executive Officer and Chairman | ||||||
(Principal Executive Officer) | ||||||
Date: November 5, 2021 |
By: |
/s/ GERALD N. HERMAN | ||||
Gerald N. Herman | ||||||
Executive Vice President and Chief Financial Officer | ||||||
(Principal Financial Officer and Principal Accounting Officer) |